The four EC molecular subtypes defined by the TCGA include: (i) the POLE ultra-mutated group comprising tumors with POLE exonuclease domain mutations that has the best prognosis, (ii) the MSI or mismatch repair deficient (MMRd) hypermutated group with intermediate prognosis, (iii) the p53 abnormal tumor group (also named “copy number high”) with the worst prognosis, (iv) and, finally, the group characterized by a low number of somatic copy number alterations (“also known as copy number low”), which presents good to intermediate prognosis. Here, POLE is linked to neoplasm.